Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 4:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 379 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Menstruation Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of The Cycle SyncingⓇ Method: A 12-Week Virtual Clinical Trial

NCT07286136
View directory record Official record
Conditions
Menstrual Cycle Disorder, Menstrual Symptoms, Hormonal Imbalance
Interventions
MyFLO App
Dietary Supplement
Lead sponsor
FLO LIVING, LLC
Industry
Eligibility
22 Years to 42 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Sep 5, 2026, 4:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of Blood Levels of Two Formulations of the Selective Hormone Receptor Modulator CDB-2914

NCT00041899
View directory record Official record
Conditions
Healthy
Interventions
CDB-2914, COB-2914
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 5, 2026, 4:21 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

KYleena Satisfaction Study / Observational Study on User Satisfaction With the Levonorgestrel Intrauterine Delivery System Kyleena (LNG-IUS 12) in New Contraceptive Users and After Switching From Another Contraceptive Method

NCT03182140
View directory record Official record
Conditions
Contraception
Interventions
Kyleena
Drug
Lead sponsor
Bayer
Industry
Eligibility
Female only
Enrollment
1,134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
12
States / cities
Lakewood, Colorado • Sarasota, Florida • Wellington, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2021 · Synced Sep 5, 2026, 4:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Contraception and Menstrual Cycle Effect on Pharmacokinetics, Pharmacodynamics and Safety in Tenofovir Vaginal Gel Use

NCT01421368
View directory record Official record
Conditions
HIV Prevention
Interventions
Tenofovir 1% vaginal gel, Depo-medroxyprogesterone acetate (DMPA), Oral contraceptive: LNG 150 mcg and EE 30 mcg
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Sep 5, 2026, 4:21 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Neural and Hormonal Influences on Sex Differences in Risk for AUD

NCT04929288
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Alcohol
Drug
Lead sponsor
Jessica Weafer
Other
Eligibility
21 Years to 26 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 5, 2026, 4:21 PM EDT
Not listed Phase 1Phase 2 Interventional

Phase I/II Trial of Endometrial Regenerative Cells (ERC) in Patients With Critical Limb Ischemia

NCT01558908
View directory record Official record
Conditions
Peripheral Vascular Diseases
Interventions
Administration of ERC
Biological
Lead sponsor
Medistem Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced Sep 5, 2026, 4:21 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Single Arm Trial of Menstrual Cups Among Economically Vulnerable Women to Reduce Bacterial Vaginosis and STIs

NCT05666778
View directory record Official record
Conditions
Bacterial Vaginosis, Vaginal Microbiome, Chlamydia Trachomatis Infection, Neisseria Gonorrheae Infection, Trichomonas Vaginitis
Interventions
Menstrual Cup
Device
Lead sponsor
Rush University Medical Center
Other
Eligibility
15 Years to 35 Years · Female only
Enrollment
408 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 5, 2026, 4:21 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Menstrual Cycle Study

NCT05999123
View directory record Official record
Conditions
Menstruation, Ovulation
Interventions
Not listed
Lead sponsor
Fitbit LLC
Industry
Eligibility
18 Years to 42 Years · Female only
Enrollment
143 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Sep 5, 2026, 4:21 PM EDT
Completed Phase 4 Interventional Results available

Medical Therapy Versus Radiofrequency Endometrial Ablation in the Initial Treatment of Menorrhagia

NCT01165307
View directory record Official record
Conditions
Menorrhagia
Interventions
Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills, Naproxen sodium pills, NovaSure® Radiofrequency Endometrial Ablation
Drug · Device
Lead sponsor
Abimbola Famuyide
Other
Eligibility
30 Years to 55 Years · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Sep 5, 2026, 4:21 PM EDT
Completed Phase 4 Interventional Results available

Ulipristal for Endometriosis-related Pelvic Pain

NCT02213081
View directory record Official record
Conditions
Endometriosis
Interventions
Ulipristal
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Sep 5, 2026, 4:21 PM EDT
Recruiting Not applicable Interventional

Impact of MEnstruation on Glycemic Response and Exercise In Females With Type 1 Diabetes

NCT06297980
View directory record Official record
Conditions
Type 1 Diabetes, Hypoglycemia, Hyperglycaemia Due to Type 1 Diabetes Mellitus, Menstruation Disturbances
Interventions
Personalized modifications to treatment to address menstrual cycle effects on glycemia
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 5, 2026, 4:21 PM EDT
Recruiting No phase listed Observational

A Registry to Gather Real World Use Data on the Cerene® Cryotherapy Device

NCT05922657
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Abnormal Uterine Bleeding, Menorrhagia
Interventions
Cerene
Device
Lead sponsor
Channel Medsystems
Industry
Eligibility
25 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
West Orange, New Jersey • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 5, 2026, 4:21 PM EDT
Completed No phase listed Observational

Cycle and Ovulation Study Expansion

NCT05852951
View directory record Official record
Conditions
Menstruation
Interventions
Not listed
Lead sponsor
Apple Inc.
Industry
Eligibility
14 Years and older · Female only
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Sep 5, 2026, 4:21 PM EDT
Not listed Phase 3 Interventional

Treatment of Endometriosis With Norethindrone Acetate ( NA) VS. Gonadotropin- Releasing Hormone (GnRH) Agonist (Lupron Depot 11.25 mg)

NCT00458458
View directory record Official record
Conditions
Endometriosis, Dysmenorrhea, Dyspareunia
Interventions
Norethindrone Acetate (NA), GnRH Agonist (Lupron Depot)
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 55 Years · Female only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced Sep 5, 2026, 4:21 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Role of Hormones in Susceptibility to Seizures in Women With Epilepsy

NCT00044252
View directory record Official record
Conditions
Epilepsy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 5, 2026, 4:21 PM EDT
Recruiting Phase 3 Interventional

A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis

NCT05862272
View directory record Official record
Conditions
Uterine Fibroids, Endometriosis
Interventions
Relugolix Combination Tablet
Drug
Lead sponsor
Sumitomo Pharma Switzerland GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
120
States / cities
Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 98 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Sep 5, 2026, 4:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Relationship Between the Menstrual Cycle and Heart Disease in Women

NCT01546454
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
Ethinyl Estradiol-Levonorgestrel combination, leuprolide acetate, Estradiol, Progesterone
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 40 Years · Female only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Sep 5, 2026, 4:21 PM EDT
Terminated No phase listed Observational

Identifying the Determinants of Bleeding and Hypermobility in Patients With Heavy Menstrual Bleeding

NCT05685199
View directory record Official record
Conditions
Hypermobile Ehlers-Danlos Syndrome, Heavy Menstrual Bleeding, Hypermobility Syndrome (Disorder)
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
12 Years to 40 Years · Female only
Enrollment
15 participants
Timeline
2024 – 2026
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 5, 2026, 4:21 PM EDT
Completed No phase listed Observational Results available

A Study to Evaluate the Effectiveness of Essure Post-NovaSure Radiofrequency Endometrial Ablation Procedure Following a Successful Essure Confirmation Test

NCT01740687
View directory record Official record
Conditions
Contraception, Menorrhagia
Interventions
ESS305 (Essure, BAY1454032), NovaSure
Device · Procedure
Lead sponsor
Bayer
Industry
Eligibility
21 Years to 50 Years · Female only
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
17
States / cities
Aurora, Colorado • Ocala, Florida • Decatur, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2023 · Synced Sep 5, 2026, 4:21 PM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 5, 2026, 4:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Impact of GABA-Enhancing Agents on Cortical GABA Concentrations Across the Menstrual Cycle in Women

NCT00676026
View directory record Official record
Conditions
Healthy
Interventions
Fluoxetine, Zolpidem, Progesterone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Sep 5, 2026, 4:21 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Stress & Premenstrual Symptoms Study

NCT02777372
View directory record Official record
Conditions
PMDD, Stress, Mood
Interventions
Sertraline
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Sep 5, 2026, 4:21 PM EDT
Completed Not applicable Interventional Results available

A CLinical Study to Evaluate the Safety And Effectiveness of the CeRene DevIce to Treat HeavY Menstrual Bleeding

NCT02842736
View directory record Official record
Conditions
Menorrhagia
Interventions
Cerene(R) Cryotherapy Device
Device
Lead sponsor
Channel Medsystems
Industry
Eligibility
25 Years to 50 Years · Female only
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
9
States / cities
Arlington Heights, Illinois • Naperville, Illinois • Fort Wayne, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 5, 2026, 4:21 PM EDT
Completed No phase listed Observational

Hormonal Influences on Inflammatory Bowel Diseases

NCT05610527
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Contraception, Menstrual Problem
Interventions
Proposed study design and randomization scenarios, Repeated measures of validated Inflammatory Bowel Disease Patient Reported Outcome Instruments, Inflammatory marker collection and assessment for correlation with PRO responses and menstrual timing
Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 5, 2026, 4:21 PM EDT